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Kaposi’s sarcoma at the University Teaching Hospital, Lusaka, 
Zambia in the antiretroviral therapy era
Owen Ngalamika1, Veenu Minhas2, and Charles Wood2
1Dermatology and Venereology Division, Department of Internal Medicine, University Teaching 
Hospital, University of Zambia School of Medicine, Lusaka, Zambia
2Nebraska Center for Virology, School of Biological Sciences, University of Nebraska-Lincoln, 
Lincoln Nebraska
Dear Editor
With great interest, we read the recent publication “Kaposi’s sarcoma in HIV-infected 
patients in South Africa: Multicohort study in the antiretroviral therapy era” by Bohlius et 
al.1 We congratulate the authors for their contribution to this field. In this study the authors 
observed a decrease in incidence of Kaposi’s sarcoma (KS) in patients treated with anti-
retroviral therapy (ART) when compared to patients who are not on ART. These results are 
encouraging because of the ongoing HIV epidemic in sub-Saharan Africa where KS is still 
one of the most prevalent cancers. Also, it is a relevant topic to study in South Africa; a 
country that has a high prevalence of both HIV and Kaposi’s sarcoma-associated 
herpesvirus (KSHV) infections.
This study is of interest to us because we have investigated the incidence and prevalence of 
KSHV infection in Zambia for more than a decade. Zambia, also a part of Southern Africa, 
has approximately 13% HIV prevalence in the adult population. It also has a high incidence 
of both epidemic and endemic forms of KS. The University teaching hospital (UTH) in 
Lusaka, Zambia is the national referral hospital. It has a well-established Dermatology and 
Venereology Division where suspected KS patients are referred and present themselves for 
diagnosis and treatment. UTH receives these patients from the highly populated Lusaka city 
and other cities and provinces throughout Zambia. Therefore, UTH records more KS cases 
than other health care centers in Zambia. Indeed, we have routinely been diagnosing KS 
even after ART became widely available in Zambia. Between 2008 and 2013 we recorded at 
least 726 pathologist confirmed KS cases. Of these, 460 (63.4%) cases were diagnosed in 
HIV infected patients (epidemic KS) and 266 (36.6%) cases in HIV negative patients 
(endemic KS). We agree with the results reported by Bohlius et al about KS incidence being 
higher in men. In our dataset, we too observed that both endemic and epidemic KS cases 
were diagnosed more frequently in men as compared to women The male:female ratio for 
epidemic KS 1.8 and for endemic cases was 1.7. (Table 1).
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We also want to take this opportunity to highlight that while ART may reduce the incidence 
of epidemic KS in HIV infected patients, the prevalence and incidence of endemic KS will 
likely remain high and remain under-reported in the current literature. Countries like Zambia 
that are a part of the “KS belt” will likely continue to bear the burden of endemic KS. It is 
anticipated that the decline observed in Western countries, where KS and KSHV infection 
was not endemic, will not be observed in KSHV endemic countries like Zambia. This is 
important to investigate because the burden of KSHV infection in sub-Saharan Africa is 
significantly higher as compared to Western countries where KSHV prevalence is lower. As 
stated by Bohlius et al, the seroprevalence of KSHV in South Africa is 30–50%. Our studies 
have shown that KSHV seroprevalence in women of childbearing age in Zambia is 40%.2, 3 
A recent study conducted in Cameroon has reported a KSHV seroprevalence of 80% in the 
general population.4 Thus, prevalence of KSHV infection in this region is significantly 
higher as compared to prevalence in US and Europe where it is generally less than 10%.5 
Whether ART alone is sufficient to substantially decrease the incidence of epidemic KS in 
this region, similar to what has been observed in United States and Europe remains to be 
determined.
We also believe that the direct comparison of studies conducted in resource rich settings to 
studies in resource limited settings should be interpreted with caution because the ART 
coverage and adherence to therapy in HIV infected patients may be vastly different. The 
authors mention that South Africa’s ART coverage of 55% of the HIV infected population is 
currently the largest. In our dataset, we observe that only 1 in 4 HIV positive patients were 
receiving ART at the time of KS diagnosis. Therefore, this data underscores the critical need 
for the majority of HIV infected patients to be covered by ART and also monitored for drug 
resistance. Therefore, it is quite likely that epidemic KS will remain a major form of HIV-
associated malignancy until the issues of ART coverage, adherence and drug resistance viral 
monitoring have been resolved. In parallel, there is a need to further understand the 
underlying mechanisms and risk factors associated with development of KS in ART treated 
HIV infected patients and in KSHV infected HIV negative patients, as seen in Zambia and 
as reported in the current study.
Yours sincerely,
Owen Ngalamika
Veenu Minhas
Charles Wood
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Table 1
Characteristics of Kaposi’s sarcoma patients diagnosed at Dermatology and Venereology Clinic at UTH, 
Lusaka, Zambia, 2008 – 2013.
Epidemic Cases
N (%)
Endemic Cases
N (%)
Total 460 266
Median Age (IQR) 34 (29–42) 35 (27–45)
Age Group
 <18 years 6 (1.3) 12 (4.5)
 18–34 years 229 (49.8) 120 (45.1)
 35–49 years 175 (38.0) 80 (30.1)
 50 or more 50 (10.9) 54 (20.3)
Gender
 Male 296 (64.3) 166 (62.4)
 Female 164 (35.7) 100 (37.6)
ART
 Yes 114 (24.8) -
 No 346 (75.2) -
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